NOVATO, Calif., May 14, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced that NASDAQ is adding Raptor to the NASDAQ Biotechnology Index (NASDAQ: NBI and XNBI). The NBI includes seasoned NASDAQ Global Market and Global Select issuers classified as biotech or pharmaceutical companies with a minimum market capitalization of $200 million, minimum daily trading volume of 100,000 shares and other eligibility requirements. More information on the index is available on NASDAQ's website at:
https://indexes.nasdaqomx.com/docs/methodology_NBI.pdf
Raptor's addition to the index is effective at the close of trading on Friday, May 18, 2012. Raptor became eligible once it effected a market tier upgrade to the NASDAQ Global Market on February 29, 2012.
"We are pleased to receive NASDAQ's recognition of Raptor's continued corporate growth in the biotechnology sector, and look forward to the additional exposure provided by our inclusion in the NBI," said Kim R. Tsuchimoto, Chief Financial Officer of Raptor.
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ("Raptor") seeks to research, produce, and deliver medicines that improve life for patients with severe, rare disorders. Raptor currently has product candidates in clinical development designed to potentially treat nephropathic cystinosis, Non-alcoholic Steatohepatitis ("NASH"), Huntington's Disease ("HD"), aldehyde dehydrogenase deficiency ("ALDH2"), and thrombotic disorder.
Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein and related proteins that are designed to target cancer and infectious diseases.
For additional information, please visit www.raptorpharma.com.
The Raptor Pharmaceutical Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7180